Evanson Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Evanson Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-667	Closed	-$109K	–	224
2019 Q4	$109K	Hold	667	–	–	0.02%	231
2019 Q3	$97K	Sell	667 -26	-4%	-$4.53K	0.02%	230
2019 Q2	$144K	Buy	693 +16	+2%	+$3.43K	0.03%	230
2019 Q1	$141K	Hold	677	–	–	0.03%	231
2018 Q4	$119K	Hold	677	–	–	0.03%	219
2018 Q3	$153K	Hold	677	–	–	0.03%	227
2018 Q2	$103K	Hold	677	–	–	0.02%	245
2018 Q1	$124K	Hold	677	–	–	0.03%	245
2017 Q4	$144K	Hold	677	–	–	0.03%	238
2017 Q3	$145K	Sell	677 -12	-2%	-$2.35K	0.03%	223
2017 Q2	$130K	Buy	689 +10	+1%	+$1.96K	0.03%	215
2017 Q1	$168K	Buy	679 +12	+2%	+$2.94K	0.04%	213
2016 Q4	$169K	Hold	667	–	–	0.05%	206
2016 Q3	$136K	Hold	667	–	–	0.04%	193
2016 Q2	$60K	Buy	667 +334	+100%	+$26.2K	0.02%	199
2016 Q1	$18K	Hold	333	–	–	0.01%	198
2015 Q4	$17K	Hold	333	–	–	0.01%	199
2015 Q3	$16K	Buy	+333	New	+$22.2K	0.01%	203

Other funds holding CRBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Evanson Asset Management's CRBP Position: Q1 2020 in Review

Evanson Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2020, closing a stake of 667 shares — an estimated $109K sold.

Evanson Asset Management first reported a position in CRBP in Q3 2015 and held it in 18 quarters. The position peaked at $169K in Q4 2016. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

Evanson Asset Management reported no remaining Corbus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Evanson Asset Management sold 667 Corbus Pharmaceuticals shares in Q1 2020, an estimated $109K.
Evanson Asset Management first reported a position in Corbus Pharmaceuticals in Q3 2015 and held it in 18 quarters.
Evanson Asset Management's Corbus Pharmaceuticals position peaked at $169K in Q4 2016.
111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on Evanson Asset Management's 13F filing for Q1 2020, filed 24 Apr 2020.